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Abstract 
Increasing evidence suggests that an exaggerated maternal systemic inflammatory response, 
as well as an angiogenic imbalance plays a central role in the pathogenesis of preeclampsia. In 
this study, we determined circulating levels of interleukin-17 (IL-17) along with those of 
angiogenic factors in healthy non-pregnant and pregnant women and preeclamptic patients, 
and examined whether serum IL-17 levels of preeclamptic patients were related to their 
clinical features and angiogenic factor concentrations. Fifty-nine preeclamptic patients, 60 
healthy pregnant women and 56 healthy non-pregnant women were involved in this case-
control study. Serum levels of IL-17A were measured by high sensitivity ELISA. Serum total 
soluble fms-like tyrosine kinase-1 (sFlt-1) and biologically active placental growth factor 
(PlGF) levels were determined by electrochemiluminescence immunoassay. For statistical 
analyses, non-parametric methods were applied. Serum IL-17 levels were significantly higher 
in preeclamptic patients than in healthy non-pregnant and pregnant women. We did not find 
any relationship between serum IL-17 concentrations of preeclamptic patients and their 
clinical features and serum sFlt-1 and PlGF levels or sFlt-1/PlGF ratios. However, elevated 
serum IL-17 level and sFlt-1/PlGF ratio was found to be additive for the risk of preeclampsia, 
as shown by the substantially higher odds ratios of their combination than of either alone. In 
conclusion, serum IL-17 levels are increased in preeclampsia, which might contribute to the 
development of the excessive systemic inflammatory response characteristic of the maternal 
syndrome of the disease. In addition, elevated serum IL-17 level and sFlt-1/PlGF ratio had an 
additive (joint) effect in the risk of preeclampsia. 
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1. Introduction 
Preeclampsia, characterized by hypertension and proteinuria developing after the 20
th
 
week of gestation in a previously normotensive woman, is a severe complication of human 
pregnancy with a worldwide incidence of 4.6 (2.7-8.2) % (Abalos et al. 2013). It is one of the 
leading causes of maternal, as well as perinatal morbidity and mortality, even in developed 
countries. Despite extensive research, the etiology and pathogenesis of preeclampsia are not 
completely understood. There is an increasing body of evidence that an exaggerated maternal 
systemic inflammatory response to pregnancy with activation of both the innate and the 
adaptive arms of the immune system, as well as an imbalance between circulating angiogenic 
and anti-angiogenic factors, plays a central role in the pathogenesis of the disease (Redman et 
al. 1999, Maynard et al. 2003, Saito et al. 2007, Molvarec et al. 2010a, Molvarec et al. 2010b, 
Szarka et al. 2010). 
There are six members of the interleukin (IL)-17-family of cytokines (IL-17A, IL-17B, 
IL-17C, IL-17D, IL-17E (IL-25) and IL-17F), while the IL-17 receptor family comprises five 
receptor subunits (IL-17RA, IL-17RB/IL-25R, IL-17RC, IL-17RD/SEF and IL-17RE) 
(Gaffen 2009). Of them, IL-17A (referred to as IL-17 in the rest of this paper), also known as 
cytotoxic T lymphocyte-associated antigen 8 (CTLA-8) in rodents, has been most extensively 
studied. IL-17 is produced by helper and cytotoxic T cells, macrophages, dendritic cells, 
natural killer, natural killer T, lymphoid tissue inducer cells and γδ T cells (Onishi and Gaffen 
2010). IL-17-producing CD4 cells have been described as a unique subset of helper T cells, 
which develop via a lineage that is distinct from the T helper type 1 (Th1) and 2 (Th2) 
lineages (Harrington et al. 2005, Park et al. 2005). Th17 cells are essential for host defence 
against microbial pathogens, particularly extracellular bacteria and fungi, some protozoa and 
viruses (O'Quinn et al. 2008). 
 An important feature of systemic inflammation in preeclampsia is the absence of Th2 
shift characteristic for physiological pregnancy, and thus the predominance of Th1-type 
immunity (Saito et al. 1999a, Saito et al. 1999b). In addition to the imbalance of Th1 and Th2 
cells, alterations in the prevalence of Th17 and regulatory T cells may also contribute to the 
development of systemic inflammation in preeclampsia (Santner-Nanan et al. 2009, 
Darmochwal-Kolarz et al. 2012). Our research group has formerly demonstrated that not only 
the prevalence of Th17 cells, but also that of IL-17-producing CD8 (Tc17) and NK cells is 
increased in preeclampsia (Toldi et al. 2011). 
 In the present study, we extended our previous observation and determined serum IL-
17 levels in a large number of healthy non-pregnant and pregnant women and preeclamptic 
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patients. We also measured circulating levels angiogenic factors, and examined whether 
serum IL-17 levels of preeclamptic patients were related to their clinical features and 
angiogenic factor concentrations. 
 
2. Materials and methods 
 
2.1. Study patients 
 Our study was designed as a case-control study. Fifty-nine preeclamptic patients, 60 
healthy pregnant women with uncomplicated pregnancies and 56 healthy non-pregnant 
women were involved in the study. The study participants were enrolled in the First 
Department of Obstetrics and Gynecology and in the Department of Obstetrics and 
Gynecology of Kútvölgyi Clinical Center, at the Semmelweis University, Budapest, Hungary. 
All women were Caucasian and resided in the same geographic area in Hungary. Exclusion 
criteria were multifetal gestation, chronic hypertension, diabetes mellitus, autoimmune 
disease, angiopathy, renal disorder, maternal or fetal infection and fetal congenital anomaly. 
None of the pregnant women were in active labor, and none had rupture of amniotic 
membranes. The healthy non-pregnant women were in the early follicular phase of their 
menstrual cycle (between cycle days 3 and 5), and none of them received hormonal 
contraception. 
 Preeclampsia was defined by increased blood pressure (≥140 mmHg systolic or ≥90 
mmHg diastolic on ≥2 occasions at least 6 hours apart) that occurred after the 20th week of 
gestation in a woman with previously normal blood pressure, accompanied by proteinuria 
(≥0.3 g/24h or ≥1 + on dipstick in the absence of urinary tract infection). Blood pressure 
returned to normal by the 12
th
 postpartum week in each preeclamptic study patient. 
Preeclampsia was regarded as severe if any of the following criteria was present: blood 
pressure≥160 mmHg systolic or ≥110 mmHg diastolic, or proteinuria≥5 g/24h (or ≥3 + on 
dipstick). Pregnant women with eclampsia or HELLP syndrome (hemolysis, elevated liver 
enzymes, and low platelet count) were not enrolled in this study. Intrauterine growth 
restriction (IUGR) was diagnosed if the fetal birth weight was below the 10
th
 percentile for 
gestational age and gender, based on Hungarian birth weight percentiles. 
 The study protocol was approved by the Regional and Institutional Committee of 
Science and Research Ethics of the Semmelweis University, and written informed consent 
was obtained from each patient. The study was conducted in accordance with the Declaration 
of Helsinki. 
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2.2. Laboratory methods 
Fasting blood samples were taken from an antecubital vein into plain tubes, and then 
centrifuged at room temperature with a relative centrifugal force of 3000 g for 10 minutes. 
The aliquots of serum were stored at -80 °C until the analyses. Serum levels of interleukin-17 
(IL-17A) were measured by high sensitivity ELISA (eBioscience, San Diego, CA, USA, Cat. 
No. BMS2017HS) according to the manufacturer’s instructions. Serum total soluble fms-like 
tyrosine kinase-1 (sFlt-1) and biologically active placental growth factor (PlGF) levels were 
determined by electrochemiluminescence immunoassay (Elecsys, Roche, Mannheim, 
Germany, Cat. No. 05109523 and 05144671, respectively) on a Cobas e 411 analyzer (Roche, 
Mannheim, Germany). 
 
2.3. Statistical analysis 
 The normality of continuous variables was assessed using the Shapiro-Wilk’s W-test. 
As the continuous variables were not normally distributed, non-parametric statistical methods 
were used. To compare continuous variables between two groups, the Mann-Whitney U-test 
was applied, whereas to compare them among multiple groups, the Kruskal-Wallis analysis of 
variance by ranks test was performed. Multiple comparisons of mean ranks for all groups 
were carried out as post-hoc tests. The Fisher exact and Pearson χ2 tests were used to compare 
categorical variables between groups. Analysis of covariance (ANCOVA) and multivariate 
logistic regression were undertaken with adjustment for BMI at blood draw. 
Statistical analyses were carried out using the following software: STATISTICA 
(version 12; StatSoft, Inc., Tulsa, Oklahoma, USA) and Statistical Package for the Social 
Sciences (version 22 for Windows; SPSS, Inc., Chicago, Illinois, USA). For all statistical 
analyses, p<0.05 was considered statistically significant. 
In the article, data are reported as median (interquartile range) for continuous variables 
and as number (percentage) for categorical variables. 
 
3. Results 
 
3.1. Patient characteristics 
 The clinical characteristics of the study participants are described in Table 1. There 
was no statistically significant difference in terms of age among the three study groups. 
Furthermore, no significant differences were observed in gestational age at blood collection 
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and the percentage of primiparas between preeclamptic patients and healthy pregnant women. 
However, all of the other clinical features presented in Table 1 differed significantly among 
our study groups. Fetal growth restriction was absent in healthy pregnant women, whereas the 
frequency of this condition was 18.6% in the preeclamptic group. Twenty-one women 
(35.6%) had severe preeclampsia and 30 patients (50.8%) experienced preterm onset (<37 
weeks) of the disease. 
 
3.2. Laboratory parameters 
 The laboratory parameters of the study subjects are displayed in Table 2. Serum IL-17 
levels were significantly higher in preeclamptic patients than in healthy non-pregnant and 
pregnant women. In addition, the proportion of women with measurable IL-17 concentration 
was significantly higher in the preeclamptic group compared to the groups of healthy non-
pregnant and pregnant women. The differences in serum IL-17 levels between preeclamptic 
patients and healthy non-pregnant and pregnant women remained significant even after 
adjustment for BMI at blood draw in ANCOVA (data not shown). Serum levels of sFlt-1 and 
PlGF, as well as sFlt-1/PlGF ratio, were significantly higher in healthy pregnant than non-
pregnant women. Preeclamptic patients had significantly higher sFlt-1 levels and sFlt-1/PlGF 
ratio and significantly lower PlGF concentrations as compared to healthy pregnant women. 
Moreover, their sFlt-1 and PlGF levels and sFlt-1/PlGF ratio were significantly higher than 
those of healthy non-pregnant women. 
 In the group of preeclamptic patients, no statistically significant differences were 
found in serum IL-17 concentrations between patients with mild and severe preeclampsia, 
between patients with preterm and term onset of the disease, or between preeclamptic patients 
with and without fetal growth restriction (data not shown). However, severely preeclamptic 
patients had significantly higher sFlt-1 levels compared to those with mild preeclampsia 
(median (25-75 percentile): 10269 (5267-15420) versus 6113 (3697-8481) pg/ml, p<0.05). In 
addition, preeclamptic patients with fetal growth restriction or onset of the disease before term 
had significantly lower PlGF concentrations than those without IUGR (median (25-75 
percentile): 70.1 (37.6-104) versus 98.9 (68.0-146) pg/ml, p<0.05) or with a disease onset at 
term (median (25-75 percentile): 73.3 (41.9-132) versus 116 (91.8-176) pg/ml, p<0.05). 
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3.3. Relationship of serum IL-17 levels of preeclamptic patients to their clinical 
characteristics and laboratory parameters 
 We also examined whether serum IL-17 levels of preeclamptic patients were related to 
their clinical features and angiogenic factor concentrations by dichotomising IL-17 levels 
based on the median value of the preeclamptic group (>0.47 pg/ml or ≤0.47 pg/ml). However, 
we did not find any relationship between serum IL-17 concentrations of preeclamptic patients 
and their clinical features and serum sFlt-1 and PlGF levels or sFlt-1/PlGF ratios. 
 Using the Receiver Operating Characteristic (ROC) curve analysis, we determined cut-
off values for serum IL-17 concentration (>0 pg/ml, sensitivity: 54.2%, specificity: 95.0%; 
area under curve (AUC) with 95% CI: 0.74 (0.65-0.81)) and sFlt-1/PlGF ratio (>31.2, 
sensitivity: 75.9%, specificity: 74.1%; AUC (95% CI): 0.81 (0.73-0.88)) to discriminate 
preeclamptic patients from healthy pregnant women. In a multiple logistic regression model 
involving both variables, measurable serum IL-17 level and elevated sFlt-1/PlGF ratio were 
found to be independent predictors of preeclampsia (odds ratios with 95% confidence 
intervals: 23.2 (5.63-95.6) and 9.39 (3.29-26.8), respectively, p<0.0001 for both; after 
adjustment for BMI at blood draw: 31.7 (5.01-200) and 16.8 (3.74-75.9), respectively, 
p<0.001 for both). Women with measurable serum IL-17 level and elevated sFlt-1/PlGF ratio 
had substantially higher odds for having preeclampsia than those with elevated sFlt-1/PlGF 
ratio or measurable serum IL-17 concentration alone (OR (95% CI): 286 (15.4-5307), 
p<0.0001 versus 7.31 (2.45-21.8), p<0.001 and 13.0 (2.54-66.4), p<0.05, respectively). 
 
4. Discussion 
 In this study, we measured circulating levels of IL-17 along with those of sFlt-1 and 
PlGF in a large number of healthy non-pregnant and pregnant women and preeclamptic 
patients. According to our findings, serum IL-17 levels are significantly higher in 
preeclamptic patients than in healthy non-pregnant and pregnant women. Serum IL-17 levels 
of preeclamptic patients were not related to their clinical features and angiogenic factor 
concentrations. However, the combination of elevated serum IL-17 level and sFlt-1/PlGF ratio 
was found to be additive for the risk of preeclampsia. 
 Previous data on circulating IL-17 levels in preeclampsia are controversial. In a study, 
measuring IL-17 levels in serum samples of 13 women with preeclampsia and 14 normal 
pregnant women with multiplex bead array, no significant difference was observed (Jonsson 
et al. 2006). It is noteworthy that the majority of IL-17 serum values in this study were below 
the detection limit of the assay. Multiplex bead array technology has a high dynamic range, 
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and it may not be optimal for evaluating analytes with very low concentration. In a recent 
study, IL-17 levels were determined in plasma samples of 40 preeclamptic and 40 
normotensive pregnant women with ELISA (Ozkan et al. 2014). The authors found lower IL-
17 levels in the preeclamptic group. However, gestational age in their control group was 
significantly higher than that of the preeclamptic group. As circulating IL-17 levels have been 
reported to increase with advancing gestation (Martinez-Garcia et al. 2011), the difference in 
gestational age might confound their results. In our study, serum IL-17 levels were evaluated 
in a larger number of preeclamptic patients and healthy pregnant women (matched for age and 
gestational age) with a high sensitivity ELISA. In addition, we also involved healthy non-
pregnant women in our study. Our results are consistent with previous studies demonstrating 
higher prevalence of peripheral blood Th17 cells and increased expression of RORc mRNA in 
peripheral blood mononuclear cells and in the decidua in preeclamptic patients (Santner-
Nanan et al. 2009, Jianjun et al. 2010, Toldi et al. 2011, Darmochwal-Kolarz et al. 2012). 
 Increased circulating IL-17 levels observed in preeclampsia might contribute to the 
development of generalized intravascular inflammatory reaction characteristic of the maternal 
syndrome of the disease. IL-17 induces pro-inflammatory responses by triggering the 
expression of other cytokines (IL-6, granulocyte colony-stimulating factor, tumor necrosis 
factor-α), chemokines (CXCL1, CXCL2, CCL20), inflammatory effectors (acute phase 
proteins, complement) and antimicrobial proteins (defensins, mucins) (Onishi and Gaffen 
2010). Indeed, preeclampsia has already been demonstrated to be associated with elevated 
amounts of pro-inflammatory cytokines, chemokines, acute phase proteins and complement 
activation products in the maternal circulation (Molvarec et al. 2009a, Derzsy et al. 2010, 
Szarka et al. 2010). Furthermore, IL-17 has been linked to the pathogenesis of several 
autoimmune and inflammatory disorders, such as rheumatoid arthritis, systemic lupus 
erythematosus, inflammatory bowel disease, psoriasis and multiple sclerosis (Onishi and 
Gaffen 2010). 
 In a rat model, IL-17 has been shown to induce circulating Th17 cells, placental 
oxidative stress, the production of autoantibodies activating the angiotensin II type 1 receptor 
(AT1-AA) and hypertension during pregnancy (Dhillion et al. 2012). Additionally, 
administration of IL-17 soluble receptor C (an inhibitor of IL-17 function) suppressed 
circulating Th17 cells, oxidative stress, AT1-AA and hypertension in the reduced uterine 
perfusion pressure (RUPP) model of preeclampsia (Cornelius et al. 2013a). Another study of 
the same research group indicated that endothelin-1 pathway is not a mechanism by which IL-
17 causes hypertension during pregnancy (Cornelius et al. 2013b). Although we did not find a 
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relationship between serum IL-17 levels and blood pressure values in our preeclamptic group, 
the process responsible for blood pressure elevation in this multifactorial disorder is more 
complex and may involve the interplay of numerous factors in addition to the effect of IL-17. 
 Accumulating data indicate the central role of circulating angiogenic factors and their 
antagonists in the development of preeclampsia (Maynard et al. 2003, Molvarec et al. 2010a, 
Molvarec et al. 2010b). In this study, we also measured serum sFlt-1 and PlGF concentrations 
by electrochemiluminescence immunoassay. However, increased sFlt-1 and decreased PlGF 
levels were not related to serum IL-17 concentrations in women with preeclampsia, 
suggesting that angiogenic imbalance and alterations in circulating IL-17 levels are 
independent mechanisms in the pathogenesis of preeclampsia. Instead, elevated serum IL-17 
level and sFlt-1/PlGF ratio had an additive (joint) effect in the risk of preeclampsia, as shown 
by the substantially higher odds ratios of their combination than of either alone. 
 In our study, the similar circulating IL-17 concentrations of preeclamptic patients 
regardless of the severity of the disease or the presence of fetal growth restriction might be 
explained by the multifactorial etiology of preeclampsia. Several genetic, behavioural and 
environmental factors need to interact to produce the complete picture of this pregnancy-
specific disorder. Our research group reported various genetic and soluble factors that were 
associated with the severity or complications of preeclampsia (Molvarec et al. 2007, Molvarec 
et al. 2008, Molvarec et al. 2009b, Rosta et al. 2009). 
 There is an increasing body of evidence for distinct preterm and term phenotypes of 
preeclampsia with differences in maternal and fetal characteristics and pathogenetic features 
(Vatten and Skjaerven 2004, Phillips et al. 2010). In our study, no significant differences were 
observed in serum IL-17 concentrations between preeclamptic patients with preterm and term 
onset of the disease. We hypothesize that the development of these two different disease 
entities converges at maternal systemic inflammation with elevated amounts of IL-17 in the 
maternal circulation. Nevertheless, further studies are required with involvement of a larger 
number of patients with preterm and especially early-onset preeclampsia (disease onset< 34 
weeks) to support our hypothesis. 
In conclusion, according to our findings, serum IL-17 levels are increased in women 
with preeclampsia, which might contribute to the development of the excessive systemic 
inflammatory response characteristic of the maternal syndrome of the disease. In addition, 
elevated serum IL-17 level and sFlt-1/PlGF ratio had an additive (joint) effect in the risk of 
preeclampsia. 
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Table 1. Clinical characteristics of healthy non-pregnant and pregnant women and 
preeclamptic patients 
 
 Healthy non-
pregnant women 
(n=56) 
Healthy pregnant 
women (n=60) 
Preeclamptic patients 
(n=59) 
Age (years) 28 (23-34) 30 (28-32) 29 (26-32) 
BMI at blood draw (kg/m
2
) 20.8 (19.6-23.0) 25.8 (24.3-27.9)
b 
29.8 (26.9-33.3)
b,d 
Smokers 13 (23.2%) 0 (0%)
b 
3 (5.1%)
a 
Primiparas n.a. 37 (61.7%) 38 (64.4%) 
Systolic blood pressure at blood 
draw (mmHg) 
110 (110-120) 110 (107-120)
 
164 (156-180)
b,d 
Diastolic blood pressure at blood 
draw (mmHg) 
80 (70-80) 70 (60-80)
b 
100 (97-110)
b,d 
Gestational age at blood draw 
(weeks) 
n.a. 36 (36-37) 37 (36-39)
 
Gestational age at delivery 
(weeks) 
n.a. 39 (38-40) 38 (37-39)
d 
Fetal birth weight (grams) n.a. 3450 (3150-3700) 3150 (2450-3500)
d 
Fetal growth restriction n.a. 0 (0%) 11 (18.6%)
d 
 
Data are presented as median (interquartile range) for continuous variables and as number 
(percentage) for categorical variables 
n.a.: not applicable; BMI: body mass index 
 
a
 p<0.05 versus healthy non-pregnant women 
b
 p<0.001 versus healthy non-pregnant women 
c
 p<0.05 preeclamptic patients versus healthy pregnant women 
d
 p<0.001 preeclamptic patients versus healthy pregnant women 
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Table 2. Laboratory parameters of healthy non-pregnant and pregnant women and 
preeclamptic patients 
 
 Healthy non-
pregnant women 
(n=56) 
Healthy pregnant 
women (n=60) 
Preeclamptic patients 
(n=59) 
Serum IL-17 level (pg/ml) 0 (0-0) 0 (0-0)
 
0.47 (0-0.53)
a,b 
Measurable serum IL-17 level 5 (8.9%) 3 (5.0%)
 
32 (54.2%)
a,b 
Serum sFlt-1 level (pg/ml) 76.3 (67.1-83.6)
*
 3252 (2509-4751)
†,a 
6814 (3736-12720)
‡,a,b 
Serum PlGF level (pg/ml) 16.2 (14.0-18.0)
*
 183 (126-307)
†,a 
98.0 (63.7-146)
‡,a,b 
Serum sFlt-1/PlGF ratio 4.79 (3.82-5.52)
*
 15.6 (8.52-36.6)
†,a 
70.5 (31.8-144)
‡,a,b 
 
Data are presented as median (interquartile range) for continuous variables and as number 
(percentage) for categorical variables 
IL-17: interleukin-17; sFlt-1: soluble fms-like tyrosine kinase-1; PlGF: placental growth 
factor 
*
 n=52   
† 
n=58   
‡ 
n=54 
 
a
 p<0.001 versus healthy non-pregnant women 
b 
p<0.001 preeclamptic patients versus healthy pregnant women 
 
